Stockscreener 앱 받기
0.369
21.10%
0.0643
시간 외 거래:
.35
-0.019
-5.15%
전일 마감가:
$0.3047
열려 있는:
$0.3047
하루 거래량:
2.37M
Relative Volume:
2.33
시가총액:
$24.39M
수익:
-
순이익/손실:
$-30.01M
주가수익비율:
-0.3025
EPS:
-1.22
순현금흐름:
$-23.94M
1주 성능:
+34.38%
1개월 성능:
+40.14%
6개월 성능:
-63.10%
1년 성능:
-64.52%
1일 변동 폭
$0.3001
$0.4042
1주일 범위
$0.2621
$0.41
52주 변동 폭
$0.217
$2.48
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability - Quantisnow
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference - StockTitan
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Yahoo Finance
OrbiMed Advisors LLC Reduces Stake in TELA Bio Inc - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance UK
Upstream Bio Rings the Opening Bell - Nasdaq
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development - Yahoo Finance UK
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum - Lelezard
Average rate on a 30-year mortgage in the US rises to the highest level in 8 weeks - Yahoo Finance
Cresco Labs to Report Third Quarter 2024 Financial Results on November 8, 2024 - Yahoo Finance
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance
Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? - Yahoo Finance
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - Quantisnow
Is Nuvation Bio Inc. (NUVB) Hedge Funds’ Favorite Penny Stock? - Yahoo Finance
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - BNN Bloomberg
Covid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna - MSN
Growing Confidence in Nuvation Bio, Inc. (NUVB) as Hedge Fund Holdings Increase to 35 - Insider Monkey
Cellipont Bioservices and Mongoose Bio Sign Agreement to Advance MGB-001, its Lead TCR-T therapy, towards the Clinic for Multiple Cancers - Longview News-Journal
Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil - The Philadelphia Inquirer
Paramount Global to Report Third Quarter Financial Results on November 8, 2024 - Yahoo Finance
SK Bioscience's U.S.-based bio company 'Pina Bio'It announced on the 8th that it has signed a contra.. - 매일경제
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Adicet Bio, Inc.'s (NASDAQ:ACET) large institutional owners must be happy as stock continues to impress, up 11% over the past week - Simply Wall St
If you bought this Breyers ice cream flavor in the past 8 years, you may be eligible for compensation - Yahoo Finance
Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in September - Defense World
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference - Business Wire
A group of women lowered their biological age by an average of 5 years in just 8 weeks. Here’s how - Yahoo Finance
Biomarker Data from Oncology Trial for Adicet Bio’s Game Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive™
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025 - Business Wire
Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World
Bluebird Bio to Cut 25% of Staff Amid Gene Therapy Struggles - BNN Bloomberg
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference - ForexTV.com
Cigna scaling back Medicare Advantage footprint in 8 states next year - Yahoo Finance
8x8 Inc executive sells over $25k in company stock By Investing.com - Investing.com South Africa
8x8 CEO sells over $48k in company stock By Investing.com - Investing.com UK
New insider Divincenzo Jonathan P. claimed no ownership of stock in the company (SEC Form 3) - Quantisnow
Retina Society 2024: Population pharmacokinetic modeling and simulation of ocular clearance of aflibercept 8 mg and 2 mg - Ophthalmology Times
SEC Form 424B5 filed by INmune Bio Inc. - Quantisnow
Indian Immunologicals Signs Pact For Clinical Development Of Zika Vaccine - Afternoon Voice
Indian Immunologicals Sign Pact For Clinical Development Of Zika Vaccine - NDTV
Seven Aussie startups that raised $206 million this week (sort of) - SmartCompany
Owning 41% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB), - Simply Wall St
SEC Form 4 filed by EVP, President, LSG Barry James - Quantisnow
Biotech startup Number 8 Bio bags $7 million to drive methane-busting mission - SmartCompany
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Chairman, President, and CEO Schwartz Norman D covered exercise/tax liability with 5,159 units of Bio-Rad A Common Stock and converted options into 10,477 units of Bio-Rad A Common Stock, increasing direct ownership by 1% to 438,238 units (SEC For - Quantisnow
Director Allison Schwartz converted options into 247 units of Bio-Rad A Common Stock and covered exercise/tax liability with 118 units of Bio-Rad A Common Stock, increasing direct ownership by 11% to 1,305 units (SEC Form 4) - Quantisnow
Natco Pharma invests USD 8 mn in bio-tech firm eGenesis - Business Standard
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference - StockTitan
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):